10.15 | 7.15 Opportunities for Liquid Biopsy Across the Continuum of Care

Time: 10:15 am
day: Day One


  • With the successful clinical adoption of LBx in late stage cancer, attention is now turning to opportunities earlier in the patient journey
  • Earlier stage cancers require integration of several biomarkers to deliver appropriate sensitivity
  • Progress is being made to generate the evidence to support clinical adoption, but regulatory and reimbursement hurdles must also be overcome